AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. BDTX
  4. [Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity

[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Black Diamond Therapeutics Director Prakash Raman acquired 5,526 shares of common stock at $2.33 per share on June 20, 2025, bringing their total direct ownership to 22,519 shares.

Key details of the transaction:

  • The shares were issued under the company's Fifth Amended and Restated Non-Employee Director Compensation Policy
  • The acquisition represents an election to receive stock in lieu of cash compensation for annual services as a non-employee director
  • The reported price is based on the closing market price of the company's common stock on June 18, 2025
  • The transaction was reported via Form 4 filing, executed by Attorney-in-Fact Brent Hatzis-Schoch

Prakash Raman, direttore di Black Diamond Therapeutics, ha acquisito 5.526 azioni ordinarie al prezzo di 2,33 $ per azione il 20 giugno 2025, portando la sua partecipazione diretta totale a 22.519 azioni.

Dettagli principali della transazione:

  • Le azioni sono state emesse secondo la Quinta Politica Modificata e Ristabilita di Compensazione per Direttori Non Dipendenti della societ脿
  • L'acquisizione rappresenta una scelta di ricevere azioni anzich茅 compenso in contanti per i servizi annuali come direttore non dipendente
  • Il prezzo riportato si basa sul prezzo di chiusura di mercato delle azioni ordinarie della societ脿 del 18 giugno 2025
  • La transazione 猫 stata comunicata tramite la presentazione del Modulo 4, eseguita dall'Avvocato Delegato Brent Hatzis-Schoch

Prakash Raman, director de Black Diamond Therapeutics, adquiri贸 5,526 acciones comunes a $2.33 por acci贸n el 20 de junio de 2025, elevando su propiedad directa total a 22,519 acciones.

Detalles clave de la transacci贸n:

  • Las acciones fueron emitidas bajo la Quinta Pol铆tica Enmendada y Restablecida de Compensaci贸n para Directores No Empleados de la empresa
  • La adquisici贸n representa una elecci贸n de recibir acciones en lugar de compensaci贸n en efectivo por servicios anuales como director no empleado
  • El precio reportado se basa en el precio de cierre de mercado de las acciones comunes de la empresa el 18 de junio de 2025
  • La transacci贸n fue reportada mediante la presentaci贸n del Formulario 4, ejecutada por el Apoderado Brent Hatzis-Schoch

Black Diamond Therapeutics鞚� 鞚挫偓 Prakash Raman鞚� 2025雲� 6鞗� 20鞚检棎 欤茧嫻 $2.33鞐� 5,526欤�鞚� 氤错喌欤茧ゼ 旆摑頃橃棳 齑� 歆侅爲 氤挫湢 欤检嫕 靾橂ゼ 22,519欤�搿� 電橂牳鞀惦媹雼�.

瓯半灅 欤检殧 雮挫毄:

  • 欤检嫕鞚� 須岇偓鞚� 鞝�5彀� 臧滌爼 氚� 鞛爼牍勲悳 牍勳瀯鞗� 鞚挫偓 氤挫儊 鞝曥眳鞐� 霐半澕 氚滍枆霅橃棃鞀惦媹雼�
  • 鞚措矆 旆摑鞚� 牍勳瀯鞗� 鞚挫偓搿滌劀 鞐瓣皠 靹滊箘鞀れ棎 雽�頃� 順勱笀 氤挫儊 雽�鞁� 欤检嫕鞚� 氚涥赴搿� 靹犿儩頃� 瓴冹瀰雼堧嫟
  • 氤搓碃霅� 臧�瓴╈潃 2025雲� 6鞗� 18鞚� 須岇偓 氤错喌欤检潣 鞁滌灔 毵堦皭 臧�瓴╈潉 旮办鞙茧 頃╇媹雼�
  • 瓯半灅電� 雽�毽澑 Brent Hatzis-Schoch鞐� 鞚橅暣 鞛戩劚霅� Form 4 鞁犼碃靹滊ゼ 韱淀暣 氤搓碃霅橃棃鞀惦媹雼�

Prakash Raman, administrateur de Black Diamond Therapeutics, a acquis 5 526 actions ordinaires au prix de 2,33 $ par action le 20 juin 2025, portant sa d茅tention directe totale 脿 22 519 actions.

D茅tails cl茅s de la transaction :

  • Les actions ont 茅t茅 茅mises conform茅ment 脿 la cinqui猫me politique modifi茅e et r茅vis茅e de r茅mun茅ration des administrateurs non salari茅s de la soci茅t茅
  • L'acquisition repr茅sente un choix de recevoir des actions plut么t qu'une r茅mun茅ration en esp猫ces pour les services annuels en tant qu'administrateur non salari茅
  • Le prix d茅clar茅 est bas茅 sur le cours de cl么ture des actions ordinaires de la soci茅t茅 au 18 juin 2025
  • La transaction a 茅t茅 d茅clar茅e via le d茅p么t du formulaire 4, ex茅cut茅 par le mandataire Brent Hatzis-Schoch

Prakash Raman, Direktor von Black Diamond Therapeutics, erwarb am 20. Juni 2025 5.526 Stammaktien zu je 2,33 $ und erh枚hte damit seinen direkten Gesamtbesitz auf 22.519 Aktien.

Wichtige Details der Transaktion:

  • Die Aktien wurden gem盲脽 der f眉nften ge盲nderten und neu gefassten Verg眉tungspolitik f眉r nicht angestellte Direktoren des Unternehmens ausgegeben
  • Der Erwerb stellt eine Wahl dar, Aktien anstelle von Barverg眉tung f眉r j盲hrliche Dienste als nicht angestellter Direktor zu erhalten
  • Der gemeldete Preis basiert auf dem Schlusskurs der Stammaktien des Unternehmens am 18. Juni 2025
  • Die Transaktion wurde mittels Formular 4 gemeldet, ausgef眉hrt vom Bevollm盲chtigten Brent Hatzis-Schoch
Positive
  • None.
Negative
  • None.

Prakash Raman, direttore di Black Diamond Therapeutics, ha acquisito 5.526 azioni ordinarie al prezzo di 2,33 $ per azione il 20 giugno 2025, portando la sua partecipazione diretta totale a 22.519 azioni.

Dettagli principali della transazione:

  • Le azioni sono state emesse secondo la Quinta Politica Modificata e Ristabilita di Compensazione per Direttori Non Dipendenti della societ脿
  • L'acquisizione rappresenta una scelta di ricevere azioni anzich茅 compenso in contanti per i servizi annuali come direttore non dipendente
  • Il prezzo riportato si basa sul prezzo di chiusura di mercato delle azioni ordinarie della societ脿 del 18 giugno 2025
  • La transazione 猫 stata comunicata tramite la presentazione del Modulo 4, eseguita dall'Avvocato Delegato Brent Hatzis-Schoch

Prakash Raman, director de Black Diamond Therapeutics, adquiri贸 5,526 acciones comunes a $2.33 por acci贸n el 20 de junio de 2025, elevando su propiedad directa total a 22,519 acciones.

Detalles clave de la transacci贸n:

  • Las acciones fueron emitidas bajo la Quinta Pol铆tica Enmendada y Restablecida de Compensaci贸n para Directores No Empleados de la empresa
  • La adquisici贸n representa una elecci贸n de recibir acciones en lugar de compensaci贸n en efectivo por servicios anuales como director no empleado
  • El precio reportado se basa en el precio de cierre de mercado de las acciones comunes de la empresa el 18 de junio de 2025
  • La transacci贸n fue reportada mediante la presentaci贸n del Formulario 4, ejecutada por el Apoderado Brent Hatzis-Schoch

Black Diamond Therapeutics鞚� 鞚挫偓 Prakash Raman鞚� 2025雲� 6鞗� 20鞚检棎 欤茧嫻 $2.33鞐� 5,526欤�鞚� 氤错喌欤茧ゼ 旆摑頃橃棳 齑� 歆侅爲 氤挫湢 欤检嫕 靾橂ゼ 22,519欤�搿� 電橂牳鞀惦媹雼�.

瓯半灅 欤检殧 雮挫毄:

  • 欤检嫕鞚� 須岇偓鞚� 鞝�5彀� 臧滌爼 氚� 鞛爼牍勲悳 牍勳瀯鞗� 鞚挫偓 氤挫儊 鞝曥眳鞐� 霐半澕 氚滍枆霅橃棃鞀惦媹雼�
  • 鞚措矆 旆摑鞚� 牍勳瀯鞗� 鞚挫偓搿滌劀 鞐瓣皠 靹滊箘鞀れ棎 雽�頃� 順勱笀 氤挫儊 雽�鞁� 欤检嫕鞚� 氚涥赴搿� 靹犿儩頃� 瓴冹瀰雼堧嫟
  • 氤搓碃霅� 臧�瓴╈潃 2025雲� 6鞗� 18鞚� 須岇偓 氤错喌欤检潣 鞁滌灔 毵堦皭 臧�瓴╈潉 旮办鞙茧 頃╇媹雼�
  • 瓯半灅電� 雽�毽澑 Brent Hatzis-Schoch鞐� 鞚橅暣 鞛戩劚霅� Form 4 鞁犼碃靹滊ゼ 韱淀暣 氤搓碃霅橃棃鞀惦媹雼�

Prakash Raman, administrateur de Black Diamond Therapeutics, a acquis 5 526 actions ordinaires au prix de 2,33 $ par action le 20 juin 2025, portant sa d茅tention directe totale 脿 22 519 actions.

D茅tails cl茅s de la transaction :

  • Les actions ont 茅t茅 茅mises conform茅ment 脿 la cinqui猫me politique modifi茅e et r茅vis茅e de r茅mun茅ration des administrateurs non salari茅s de la soci茅t茅
  • L'acquisition repr茅sente un choix de recevoir des actions plut么t qu'une r茅mun茅ration en esp猫ces pour les services annuels en tant qu'administrateur non salari茅
  • Le prix d茅clar茅 est bas茅 sur le cours de cl么ture des actions ordinaires de la soci茅t茅 au 18 juin 2025
  • La transaction a 茅t茅 d茅clar茅e via le d茅p么t du formulaire 4, ex茅cut茅 par le mandataire Brent Hatzis-Schoch

Prakash Raman, Direktor von Black Diamond Therapeutics, erwarb am 20. Juni 2025 5.526 Stammaktien zu je 2,33 $ und erh枚hte damit seinen direkten Gesamtbesitz auf 22.519 Aktien.

Wichtige Details der Transaktion:

  • Die Aktien wurden gem盲脽 der f眉nften ge盲nderten und neu gefassten Verg眉tungspolitik f眉r nicht angestellte Direktoren des Unternehmens ausgegeben
  • Der Erwerb stellt eine Wahl dar, Aktien anstelle von Barverg眉tung f眉r j盲hrliche Dienste als nicht angestellter Direktor zu erhalten
  • Der gemeldete Preis basiert auf dem Schlusskurs der Stammaktien des Unternehmens am 18. Juni 2025
  • Die Transaktion wurde mittels Formular 4 gemeldet, ausgef眉hrt vom Bevollm盲chtigten Brent Hatzis-Schoch
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Raman Prakash
(Last) (First) (Middle)
C/O BLACK DIAMOND THERAPEUTICS, INC.
ONE MAIN STREET, 14TH FLOOR
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A(1) 5,526 A $2.33(2) 22,519 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025.
/s/ Brent Hatzis-Schoch, Attorney-in-Fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many shares of BDTX stock did Director Raman Prakash acquire on June 20, 2025?

According to the Form 4 filing, Director Raman Prakash acquired 5,526 shares of BDTX common stock on June 20, 2025.

What was the price per share for BDTX Director Prakash's stock acquisition?

The shares were acquired at a price of $2.33 per share, based on the closing market price of BDTX's common stock on June 18, 2025.

Why did BDTX Director Raman Prakash receive these shares?

The shares were issued as compensation in lieu of cash payment for annual services as a non-employee director, according to BDTX's Fifth Amended and Restated Non-Employee Director Compensation Policy.

How many BDTX shares does Raman Prakash own after this transaction?

Following this transaction, Raman Prakash directly owns 22,519 shares of BDTX common stock.

What type of ownership does Raman Prakash have in these BDTX shares?

Raman Prakash has direct ownership (D) of the shares, as indicated in Column 6 of Table I in the Form 4 filing.
Stock BDTX logo
Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

BDTX Rankings

#6226 Ranked by Market Cap
N/A Ranked by Dividends

BDTX Latest News

Aug 7, 2025
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
May 29, 2025
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 12, 2025
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Mar 31, 2025
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Mar 19, 2025
Servier and Black Diamond Therapeutics Announce聽Global Licensing Agreement for BDTX-4933,聽A Targeted Oncology Therapy

BDTX Latest SEC Filings

Aug 7, 2025
[10-Q] Black Diamond Therapeutics, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] Black Diamond Therapeutics, Inc. Reports Material Event
Jun 20, 2025
[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity

BDTX Stock Data

152.96M
56.32M
0.63%
83.41%
10.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE